Actively Recruiting
4SCAR19U T Cells Targeting B Cell Malignancies
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2023-10-12
30
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product, 4SCAR19U T cells. The study also aims to learn more about the function of the 4SCAR19U T cells and their persistence in patients. This is a phase I trial enrolling patients from multiple clinical centers.
CONDITIONS
Official Title
4SCAR19U T Cells Targeting B Cell Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age older than 6 months
- Primary B cell surface expression of CD19
- Karnofsky Performance Status (KPS) score over 80 points
- Expected survival time more than 1 month
- Hemoglobin level greater than 80 g/L
- No contraindications to blood cell collection
You will not qualify if you...
- Presence of other active diseases making treatment response hard to assess
- Uncontrolled bacterial, fungal, or viral infections
- Living with HIV
- Active hepatitis B or C infection
- Pregnant or nursing mothers
- Systemic steroid treatment within one week prior to treatment
- Previous failed CAR-T cell therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shenzhen Geno-Immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
Research Team
L
Lung-Ji Chang, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here